SCHEMBL682875

SCHEMBL682875

Cc1ccc(NC(=O)c2ccc(N)cc2)cc1

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 10/20 0.81
NPC1 O15118 9/20 0.81
POLB P06746 2/20 0.81
MEN1 O00255 2/20 0.81
LMNA P02545 2/20 0.81
KMT2A Q03164 2/20 0.81
PKM P14618 2/20 0.81
APEX1 P27695 1/20 0.81
TDP1 Q9NUW8 1/20 0.81
SMN1; SMN2 Q16637 4/20 0.68
MAPT P10636 3/20 0.68
PTGS1 P23219 2/20 0.65
CA12 O43570 1/20 0.63
CA1 P00915 1/20 0.63
CA2 P00918 1/20 0.63
CA9 Q16790 1/20 0.63
TP53 P04637 2/20 0.62
NAMPT P43490 1/20 0.58
KDM4E B2RXH2 1/20 0.58
MCL1 Q07820 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23898944 1.00 RAB9A (0.81) RAB9ANPC1POLBMEN1LMNA
SCHEMBL19601411 1.00 RAB9A (0.81) RAB9ANPC1POLBMEN1LMNA
SCHEMBL678705 1.00 RAB9A (0.81) RAB9ANPC1POLBMEN1LMNA
SCHEMBL16436156 1.00 RAB9A (0.81) RAB9ANPC1POLBMEN1LMNA
SCHEMBL23805541 0.95 NPC1 (0.73) RAB9ANPC1POLBMEN1LMNA
SCHEMBL1353478 0.90 POLB (1.00) RAB9ANPC1POLBMEN1LMNA
SCHEMBL137276 0.90 POLB (1.00) RAB9ANPC1POLBMEN1LMNA
SCHEMBL30319980 0.90 POLB (1.00) RAB9ANPC1POLBMEN1LMNA
SCHEMBL2128727 0.90 POLB (1.00) RAB9ANPC1POLBMEN1LMNA
SCHEMBL9681496 0.90 POLB (1.00) RAB9ANPC1POLBMEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0213572-A1 3-and 4-amino-N(alkyl phenyl) benzamide compounds and composition containing same as anticonvulsant drugs Research Corporation Technologies, Inc. (a Delaware corp.) (US) 1987-03-11 EP claimed
CN-119704787-A Medium conveying pipe and application thereof 万华化学集团股份有限公司 2025-03-28 CN disclosed
US-20180186935-A1 POLYIMIDE FILM, ORGANIC ELECTROLUMINESCENT ELEMENT, TRANSPARENT ELECTRO-CONDUCTIVE LAMINATE, TOUCH PANEL, SOLAR CELL, AND DISPLAY DEVICE JXTG NIPPON OIL & ENERGY CORPORATION (JP) 2018-07-05 US disclosed
US-9682931-B2 Aryloyl(oxy or amino)pentafluorosulfanylbenzene compound, pharmaceutically acceptable salt thereof, and prodrugs thereof UBE INDUSTRIES, LTD. (JP) 2017-06-20 US disclosed
US-20160244407-A1 ARYLOYL(OXY OR AMINO)PENTAFLUOROSULFANYLBENZENE COMPOUND, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PRODRUGS THEREOF UBE INDUSTRIES, LTD. (JP) 2016-08-25 US disclosed
US-20110269758-A1 NAPHTHYRIDINONES AS PROTEIN KINASE INHIBITORS MERCK PATENT GMBH (DE) 2011-11-03 US disclosed
US-20110269758-A1 NAPHTHYRIDINONES AS PROTEIN KINASE INHIBITORS MERCK PATENT GMBH (DE) 2011-11-03 US disclosed
WO-2010002779-A2 NAPHTHYRIDININONES AS AURORA KINASE INHIBITORS MERCK SERONO S.A. (CH) 2010-01-07 WO disclosed
US-5064862-A 4-Amino-2*,6*-Dimethylbenzanilide RESEARCH CORPORATION (US) 1991-11-12 US disclosed
EP-0213572-B1 3-AND 4-AMINO-N(ALKYL PHENYL) BENZAMIDE COMPOUNDS AND COMPOSITION CONTAINING SAME AS ANTICONVULSANT DRUGS Research Corporation Technologies, Inc. (a Delaware corp.) (US) 1991-07-03 EP disclosed
EP-0213572-A1 3-and 4-amino-N(alkyl phenyl) benzamide compounds and composition containing same as anticonvulsant drugs Research Corporation Technologies, Inc. (a Delaware corp.) (US) 1987-03-11 EP disclosed
US-4638014-A AMINOBENZANILIDES RESEARCH CORPORATION (US) 1987-01-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110269758-A1 NAPHTHYRIDINONES AS PROTEIN KINASE INHIBITORS AURKA, AURKC, AURKB RAB9A 2275/4885NPC1 1978/4885POLB 435/4885
US-20160244407-A1 ARYLOYL(OXY OR AMINO)PENTAFLUOROSULFANYLBENZENE COMPOUND, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PRODRUGS THEREOF SLCO1B1, SLCO2B1, SLCO1B3 RAB9A 793/4885NPC1 1429/4885POLB 3790/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.